CRISPR Therapeutics AG (CRSP) FCF Margin (2016 - 2026)
CRISPR Therapeutics AG's (CRSP) quarterly FCF Margin came in at 7503.5% in Q1 2026, down 124304.0% year-on-year from N/an in Q1 2025, and up 30.34% quarter-over-quarter from 10771.99% in Q4 2025.
CRISPR Therapeutics AG (CRSP) FCF Margin (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG has disclosed FCF Margin across 11 years of filings, most recently posting 7503.5% for Q1 2026.
- FCF Margin for Q1 2026 came in at 7503.5%, down 124304.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 9777.63% (down 896512.0% YoY), and the FY2025 annual result was 9855.5%, down 947246.0% from the prior year.
- FCF Margin came in at 7503.5% for Q1 2026 at CRISPR Therapeutics AG, up from 10771.99% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 21633.13% in Q1 2024 to a low of 2426616.67% in Q4 2022.
- The 5-year median for FCF Margin is 10150.22% (2025), against an average of 168509.85%.
- Across the five-year window, FCF Margin plunged 242536479 bps in 2022 and jumped 242656855 bps in 2023, its largest moves.
- CRISPR Therapeutics AG's FCF Margin stood at 2426616.67% in 2022, then surged by 100 bps to 48.12% in 2023, then sank by 183 bps to 136.0% in 2024, then sank by 7821 bps to 10771.99% in 2025, then soared by 30 bps to 7503.5% in 2026.
- The last three FCF Margin figures came in at 7503.5% (Q1 2026), 10771.99% (Q4 2025), and 9528.46% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | CRISPR Therapeutics AG | 5.21 Bn | 2.76 Bn | - | -7,503.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7,503.50% |
| Dec 31, 2025 | -10,771.99% |
| Sep 30, 2025 | -9,528.46% |
| Jun 30, 2025 | -12,779.93% |
| Mar 31, 2025 | -6,260.46% |
| Dec 31, 2024 | -136.00% |
| Sep 30, 2024 | -17,796.01% |
| Jun 30, 2024 | -18,624.56% |
| Mar 31, 2024 | 21,633.13% |
| Dec 31, 2023 | -48.12% |
| Jun 30, 2023 | -196.04% |
| Mar 31, 2023 | 6.17% |
| Dec 31, 2022 | -2,426,616.67% |
| Sep 30, 2022 | -90,592.55% |
| Jun 30, 2022 | -101,929.11% |
| Mar 31, 2022 | -15,013.51% |
| Dec 31, 2021 | -1,251.87% |
| Sep 30, 2021 | -9,716.02% |
| Jun 30, 2021 | 89.74% |
| Mar 31, 2021 | -20,317.25% |